Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 327Neoplasm Metastasis 31Advanced Breast Cancer 19Neoplasms 17Ovarian Neoplasms 11Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Prostatic Neoplasms 7Endometrial Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Breast Diseases 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms by Site 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Recurrence 3Multiple Endocrine Neoplasia Type 1 3Head and Neck Neoplasms 3Breast Neoplasm Female 3Uterine Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2Hyperglycemia 2HER2-positive Metastatic Breast Cancer 2HER2-positive Breast Cancer 2

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Letrozole 2exemestane 1eribulin 1dalpiciclib 1Tamoxifen 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HR Positive HER2 Negative Advanced Breast Cancer × Fulvestrant × Breast × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡